Actively Recruiting
A Clinical Efficacy Study of Asiaticoside for Treating Overweight/Obesity
Led by Shanghai Zhongshan Hospital · Updated on 2025-12-24
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the clinical effects of asiaticoside tablets, a traditional herbal medicine component, in adults with overweight or obesity. Asiaticoside is known for its potential to reduce body weight, fat mass, and improve metabolic health based on animal studies. This exploratory interventional study aims to assess these effects in humans, focusing on changes in metabolic rate and body weight. Participants receive asiaticoside tablets at a dose of 60 mg three times daily for 12 weeks. This single-arm study involves continuous oral administration during this period to observe the impact on various health measures related to overweight and obesity. Throughout the study, participants will undergo assessments of metabolic rate and body weight at baseline, week 4, and week 12. Additional measurements include body mass index, body fat percentage, waist circumference, blood pressure, lipid profiles, blood sugar control markers, insulin sensitivity, inflammation markers, and liver health. Safety and health status will be monitored, with total participation lasting at least 12 weeks.
CONDITIONS
Brief Title
Asiaticoside for Treating Overweight/Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older, male or female.
- Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m².
- Able and willing to provide written informed consent.
You will not qualify if you...
- Active pulmonary tuberculosis, malignant tumors, HIV infection, or other severe infectious or immunocompromised conditions.
- Severe liver injury (AST or ALT > 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR < 30 mL/min/1.73 m²).
- Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months.
- Severe gastrointestinal disorders or history of gastrointestinal surgery within the past year.
- Secondary causes of obesity such as Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, acromegaly, or drug-induced obesity.
- Currently receiving other anti-obesity treatments, previous bariatric surgery, or >5% body weight reduction within the past 3 months.
- Current smoker or habitual smoker within the past 3 months.
- Type 1 or type 2 diabetes mellitus or currently taking hypoglycemic medications.
- Pregnancy, planning pregnancy, or breastfeeding.
- Unable to complete a 3-month follow-up due to health conditions or relocation.
- Participation in any clinical study within the past 4 weeks.
- Other conditions considered unsuitable by investigators.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants take Asiaticoside tablets 60mg three times daily for 12 weeks to treat overweight or obesity.
Weekly visits for 12 weeks
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200030
Actively Recruiting
Research Team
J
Jingjing JIANG, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here